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Abstract
Background: Biologically active natural products continue to be
useful in the exploration and control of intracellular signaling
processes. For example, the sesquiterpene lactone parthenolide
from the anti-inflammatory medicinal herb Feverfew (Tanacetum
parthenium) appears to inhibit the pro-inflammatory signaling
pathway. Parthenolide’s direct molecular target, however, remains
unknown. We set out to identify the molecular mechanisms of
parthenolide’s anti-inflammatory activity.
Results : A parthenolide affinity reagent was synthesized and
shown to bind directly to and inhibit IUB kinase L (IKKL), the
kinase subunit known to play a critical role in cytokine-mediated
signaling. Mutation of cysteine 179 in the activation loop of IKKL
abolished sensitivity towards parthenolide. Moreover, we showed
that parthenolide’s in vitro and in vivo anti-inflammatory activity
is mediated through the K-methylene Q-lactone moiety shared by
other sesquiterpene lactones.
Conclusions: In recent years, the multi-subunit IKK complex
has been shown to be responsible for cytokine-mediated stimula-
tion of genes involved in inflammation and as such represents an
attractive target for pharmaceutical intervention. Our finding that
parthenolide targets this kinase complex provides a possible
molecular basis for the anti-inflammatory properties of parthe-
nolide. In addition, these results may be useful in the development
of additional anti-inflammatory agents. ß 2001 Elsevier Science
Ltd. All rights reserved.
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1. Introduction
Nuclear factor-UB (NF-UB) is a dimeric transcription
factor that activates the expression of many genes involved
in the in£ammatory process. In unstimulated cells, NF-UB
is retained in the cytoplasm via interaction with its inhib-
itor IUB [1]. In response to various pro-in£ammatory stim-
uli, IUB is phosphorylated by the IUB kinase complex
(IKK). This leads to the ubiquitination and subsequent
proteasome-mediated degradation of IUB, allowing NF-
UB to enter the nucleus. The IKK complex is composed
of two catalytic subunits, IKKK and IKKL, as well as a
third non-catalytic subunit, IKKQ or NEMO (NF-UB es-
sential modulator) [2^6]. Recent murine gene ‘knock-out’
studies provide important insights into the understanding
of the functions of the components of IKK complex.
IKKK has been shown to be important in early embryonic
development of the skin and skeletal system [7]. On the
other hand, IKKL and NEMO are indispensable for cyto-
kine signaling. For example, in IKKL knock-out cells,
NF-UB is unresponsive to tumor necrosis factor K
(TNFK) or interleukin-1 stimulation [8]. The recent iden-
ti¢cation of the additional putative upstream IKK kinases
IKKO [9] and TBK1/NAK [10,11] suggests that the signal-
ing cascade leading to IKK complex activation is not fully
understood.
The popularity of medicinal herbs has grown signi¢-
cantly in recent years despite a dearth of information re-
garding their modes of action and continuing concerns
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over their e⁄cacy [12]. Recent e¡orts to elucidate the
mechanisms of action of several anti-in£ammatory herbs
have focused on a class of compounds, sesquiterpene lac-
tones, that are believed to be the active components of
these herbal medicines [13^16]. Several plant-derived ses-
quiterpene lactones have been shown to inhibit the activa-
tion of NF-UB. Investigations into the molecular mecha-
nisms of sesquiterpene lactone-mediated NF-UB inhibition
have yielded interesting ¢ndings. For example, the sesqui-
terpene lactone helenalin from the medicinal herb Arnica
montana has been suggested to alkylate selectively the p65
subunit of NF-UB, although no direct chemical proof has
been o¡ered in support of this hypothesis [17,18]. On the
other hand, parthenolide (Fig. 1), an abundant sesquiter-
pene lactone found in the medicinal herb Feverfew (Tana-
cetum parthenium), has been reported to inhibit NF-UB
activation via targeting an unknown signaling component
upstream of IUB [19]. Given the lack of information re-
garding the exact molecular mode(s) of action of sesqui-
terpene lactones, we initiated our study to identify the
direct target of parthenolide.
Here we show that parthenolide speci¢cally binds to and
inhibits IKKL resulting in the loss of NF-UB activation.
Moreover, parthenolide-mediated inhibition of a constitu-
tively active IKKL mutant demonstrates that parthenolide
acts directly at the level of IKKL to inhibit the NF-UB
activation. This conclusion is supported by the ¢nding
that a single amino acid substitution in the activation
loop (C179A) of IKKL abolishes parthenolide’s IKKL in-
hibitory activity. Mass spectrometric analysis con¢rmed
that the tryptic fragment of IKKL containing C179 was
modi¢ed by parthenolide. Furthermore, a parthenolide de-
rivative that does not bind IKKL lacks both in vitro and
in vivo anti-in£ammatory activity. Taken together, these
data provide a molecular mechanism for the anti-in£am-
matory property of parthenolide.
2. Results
2.1. Parthenolide speci¢cally binds to and inhibits IKKL
The sesquiterpene lactone parthenolide has been re-
ported to inhibit IUB phosphorylation, however, not
through direct inhibition of IKKK, IKKL or the upstream
kinase MEKK1 [19]. To determine if parthenolide medi-
ates its anti-in£ammatory activity through IKK complex
inhibition, human cervical carcinoma (HeLa) cells were
treated with TNFK for di¡erent lengths of time alone or
preceded by 1 h preincubation with parthenolide (Fig. 2).
HeLa cells respond to TNFK treatment by rapidly induc-
Fig. 1. Structure of parthenolide, reduced parthenolide (RP) and bio-
tinylated parthenolide.
Fig. 2. Parthenolide inhibits TNFK-mediated NF-UB DNA binding activity and IKK activity. Cell lysates from HeLa cells treated with 30 WM parthe-
nolide for 1 h prior to TNFK induction (20 ng/ml) were analyzed for NF-UB and Oct1 DNA binding activity by electrophoretic mobility shift assays
(EMSA). Ns, non-speci¢c bands. IKK complexes were immunoprecipitated (IP) from the same samples with anti-IKKK antibody and kinase activity
(KA) was assayed using GST-IUBK (1^54) as substrate. The amount of IKK complex immunoprecipitated was veri¢ed by immunoblotting (IB) with
anti-IKKL antibody.
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ing NF-UB DNA binding activity. Using electrophoretic
mobility shift assays (EMSAs), we found that TNFK-in-
duced NF-UB DNA binding activity was ¢rst detected
within 5 min and peaked at 30 min. In contrast, pretreat-
ment with 30 WM parthenolide abolished the TNFK-stimu-
lated NF-UB DNA activity but had no e¡ect on the DNA
binding activity of an unrelated transcription factor Oct1.
The peak in NF-UB DNA binding activity was preceded
by an increase in IKK activity as measured in IKK im-
munocomplex kinase assays using glutathione S-transfer-
ase (GST)-IUB (residues 1^54) fusion protein as substrate
(Fig. 2). Parthenolide dramatically abolished this TNFK-
stimulated kinase activity.
In order to identify the molecular target of this potent
anti-in£ammatory sesquiterpene lactone, we synthesized a
biotinylated a⁄nity derivative of parthenolide (Fig. 1).
This analog, which also inhibits TNFK-stimulated NF-
UB DNA binding activity (data not shown), was incubated
with HeLa cells at increasing concentrations. A⁄nity pu-
ri¢cation of biotinylated proteins using streptavidin resin
followed by anti-IKKL immunoblot analysis demonstrated
that parthenolide formed a covalent adduct with IKKL, in
a dose-dependent manner (Fig. 3A). Consistent with this
¢nding, the converse experiment showed that biotinylated
parthenolide was detected in immunoprecipitations of the
Fig. 3. Biotinylated parthenolide speci¢cally labels endogenous and overexpressed IKKL. HeLa cells alone (A,B,E) or transfected with Flag epitope-
tagged IKKL (C,D) were treated with various concentrations of biotinylated parthenolide for 1 h. The IKK complex was immunoprecipitated from cell
lysates with (A,C,E) Soft-link1 avidin resin (SA) (Promega), (B) anti-IKKK, or (D) anti-Flag (M2) antibodies. (E) The speci¢city of the biotinylated
parthenolide for IKKL was shown using cells pretreated for 1 h with increasing concentrations of parthenolide before subsequent challenge with bio-
tinylated parthenolide. Immunoprecipitated proteins were resolved by SDS^PAGE and analyzed by immunoblotting with anti-IKKL (A,B,D,E), anti-
Flag antibodies (C) or streptavidin-horseradish peroxidase conjugate (B,D).
Fig. 4. Parthenolide inhibits constitutively active wild-type but not
Cys179Ala (C179A) IKKL. (A) HeLa cells transfected with Flag-tagged
constitutively active (SS/EE) mutant IKKL were treated with increasing
concentrations of parthenolide for 1 h. IKK activity was measured in
anti-Flag (M2) immunocomplex kinase assays using GST-IUBK (1^54).
Immunoprecipitated IKKL levels were determined by immunoblot anal-
ysis with anti-Flag antibodies. (B) Constitutively active SS/EE IKKL
with an additional mutation exchanging cysteine 179 for alanine
(C179A) was overexpressed in HeLa cells. Transfected cells were incu-
bated in the absence or presence of 40 WM parthenolide for 60 min and
the resulting GST-IUB (1^54) kinase assay measured as in A.
CHBIOL 114 9-8-01
Research Paper Parthenolide targets IKKL B.H.B. Kwok et al. 761
IKK complex from biotinylated parthenolide-treated cells
(Fig. 3B). Biotinylated IKKK was also detected in these
experiments (data not shown) indicating an interaction
between this second IKK catalytic subunit and partheno-
lide. The IKKL :biotinylated parthenolide results were cor-
roborated in transient IKKL overexpression assays. Using
epitope-tagged IKKL (Flag-IKKL), a direct covalent inter-
action between biotinylated parthenolide and IKKL was
observed in both streptavidin-resin pull-down (Fig. 3C)
and anti-Flag immunoprecipitation experiments (Fig.
3D). Moreover, pretreatment with increasing concentra-
tions of parthenolide blocked biotinylated parthenolide
binding to endogenous IKKL (Fig. 3E). This observation
demonstrates that the covalent interaction between parthe-
nolide and IKKL is speci¢c and saturable.
2.2. IKKL inhibition by parthenolide is independent of
upstream kinases
The IKK complex acts as a convergence point for a
variety of upstream activating kinases, such as MEKK
[20], NIK [21,22], and NAK [10,11]. To exclude the pos-
sibility that parthenolide prevents IKKL activation via in-
hibition of an upstream kinase, constitutively active IKKL
was tested for sensitivity to parthenolide. An epitope-
tagged IKKL derivative (Flag-SS/EE IKKL) was rendered
constitutively active by substitution of serine residues 177
and 181, known to be phosphorylated in vivo, with neg-
atively charged residues (i.e., glutamate) to mimic the ac-
tivating phosphorylation at those sites [23,24]. Anti-Flag
immunoprecipitates prepared from HeLa cells transfected
Fig. 5. Reduced parthenolide lacks the ability to inhibit in vivo and in vitro NF-UB signaling. (A) Murine ear edema assay. Parthenolide, reduced par-
thenolide (RP) or vehicle (DMSO:methanol, 1:3) was applied to the ears of mice for 15 min followed by PMA treatment. Ear thickness was measured
6 h after PMA application. (B) HeLa cells were pretreated with or without parthenolide or reduced parthenolide for 1 h prior to 1 h incubation with
biotinylated parthenolide. Biotinylated proteins were puri¢ed with SA, resolved by SDS^PAGE and visualized by anti-IKKL immunoblot analysis (IB).
(C) The NF-UB DNA binding activity in HeLa cells treated with parthenolide, reduced parthenolide or vehicle (DMSO) for 1 h and induced with
TNFK (20 ng/ml) for 30 min was tested by EMSA. (D) The e¡ect of parthenolide and reduced parthenolide in inhibiting NF-UB-induced gene expres-
sion was tested using the Promega dual-luciferase reporter system. Transfected cells were then pretreated with parthenolide, reduced parthenolide, or ve-
hicle (DMSO) for 1 h followed by a 5 h TNFK (10 ng/ml) stimulation.
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with constitutively active IKKL were found to induce
GST-IUB (1^54) phosphorylation in immunocomplex ki-
nase assays (Fig. 4A). More importantly, this constitu-
tively active IKK activity was inhibited by parthenolide
in a dose-dependent manner.
The fact that parthenolide inhibited this kinase activity,
independently of any upstream activating kinases, indi-
cates that parthenolide targets IKKL directly rather than
by inhibiting an activating kinase upstream of IKKL. This
is further supported by the use of an IKKL derivative
mutated at cysteine 179. This residue lies in the activation
loop of the kinase between the two serine residues that are
phosphorylated in response to pro-in£ammatory cyto-
kines. Moreover, cysteine 179 has recently been shown
to be a site for modi¢cation by two IKKL inhibitors,
arsenite and cyclic prostaglandins [25,26]. Introduction
of the C179A mutation into SS/EE IKKL rendered a con-
stitutively active IKKL resistant to 40 WM parthenolide, a
concentration that e¡ectively inhibited the kinase activity
of SS/EE IKKL (Fig. 4B). We con¢rmed that the peptide
containing C179 was modi¢ed by parthenolide by tandem
mass spectrometric sequencing analysis of tryptic peptides
from parthenolide-treated recombinant IKKL (data not
shown). These results demonstrate that IKKL is the direct
target mediating the anti-in£ammatory activity of parthe-
nolide.
2.3. Parthenolide’s exocyclic methylene is required for in
vivo and in vitro anti-in£ammatory activity
Many anti-in£ammatory sesquiterpene lactones possess
an exocyclic methylene moiety as part of a Q-lactone
group, which can serve as a site for covalent modi¢cation
via a Michael addition reaction [27]. Parthenolide, how-
ever, also possesses an epoxide moiety, which is a second
site for potential nucleophilic attack by an amino acid side
chain. Given the presence of these two electrophilic sites
on parthenolide, it was not possible a priori to determine
the mechanism of covalent modi¢cation with IKKL. To
test whether the exocyclic methylene is responsible for
parthenolide’s anti-in£ammatory activity, the natural
product was modi¢ed to yield reduced parthenolide (Fig.
1). Employing the murine ear edema assay of in£amma-
tion, the tumor promoter phorbol myristate acetate
(PMA) was applied with or without parthenolide to the
ears of mice and the resulting swelling was measured 6 h
later. As demonstrated previously [28], parthenolide sig-
ni¢cantly reduces the PMA-induced contact sensitivity in
this in vivo assay. However, using reduced parthenolide,
we show in parallel experiments that the in vivo anti-in-
£ammatory activity of parthenolide is lost with the ab-
sence of the exocyclic methylene (Fig. 5A). We next tested
reduced parthenolide for its ability to form the IKKL :par-
thenolide protein adduct observed with the natural prod-
uct. While pretreatment of cells with 30 WM parthenolide
e¡ectively blocked subsequent biotin^parthenolide interac-
tion with IKKL, 40 WM reduced parthenolide did not in-
hibit this interaction (Fig. 5B). In addition, reduced par-
thenolide also failed to inhibit both TNFK-induced NF-UB
DNA binding activity (Fig. 5C) and NF-UB-mediated
transcription (Fig. 5D) as measured by EMSA and lucif-
erase reporter assays, respectively. Thus, protein:natural
product adduct formation most likely occurs via nucleo-
philic attack by an amino acid side chain of IKKL on the
K,L unsaturated ester of parthenolide.
3. Discussion
The ¢ndings presented here provide the ¢rst evidence
that parthenolide, the active component of the widely
used anti-in£ammatory herb Feverfew, directly targets
IKKL. Using biotinylated parthenolide, we demonstrate
that parthenolide covalently binds IKKL at similar con-
centrations required to inhibit NF-UB activation. More-
over, we show that this interaction is saturable and speci¢c
since excess parthenolide can compete for biotinylated
parthenolide binding to IKKL.
A number of kinases have been reported to be upstream
of the IKK complex in the NF-UB signaling pathway.
Overexpression of protein kinases MEKK or NIK leads
to IKKL activation [20,29,30] and, recently, additional
candidate kinases proposed to be upstream of IKK have
been identi¢ed [10,11,31]. Since IKKL, IKKK, and the up-
stream kinase MEKK1 have been previously reported not
to be the target of parthenolide [19], and we show here
that parthenolide inhibits IUB phosphorylation in response
to TNFK, it was important to determine if parthenolide
directly inhibits IKKL or the activity of an upstream IKK
kinase. We show that parthenolide e¡ectively inhibits the
IKK activity of a constitutively active IKKL (SS/EE mu-
tant), thus demonstrating that parthenolide acts at the
level of IKKL. Moreover, a single amino acid substitution
(C179A) in the kinase activation loop of this constitutively
active IKKL renders it insensitive to parthenolide. Given
the lack of parthenolide sensitivity in the C179A mutant,
this cysteine residue is a likely candidate for the site of
covalent modi¢cation by parthenolide. This possibility is
supported by tandem mass spectrometric tryptic peptide
sequence analysis, which demonstrated that the tryptic
peptide containing C179 was modi¢ed by parthenolide.
Interestingly, two other IKKL inhibitors have been re-
cently shown to target this cysteine residue [25,26]. The
K,L unsaturated carbonyl group of prostaglandin A1 was
shown to be essential for the covalent modi¢cation of
IKKL, putatively via interaction with cysteine 179 [26].
Similarly, modi¢cation of cysteine 179 of IKKL has been
proposed to mediate the pathological e¡ects of arsenite
[25]. Although additional IKKL inhibitors have been de-
scribed, it remains to be determined if cysteine 179 plays a
role in mediating their inhibitory activities [23,32,33].
The molecular mechanism of IKKL inhibition by par-
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thenolide remains unknown. In general, phosphorylation
of a kinase’s activation loop induces a conformational
change that allows substrate access to the active site [34].
Since the putative binding site, cysteine 179, lies between
the two serines that are phosphorylated in response to
TNFK, one model for parthenolide’s IKKL inhibitory ac-
tivity is that the binding of parthenolide to IKKL prevents
phosphorylation of these serines by upstream activating
kinases. However, the fact that parthenolide can inhibit
a constitutively active IKKL (SS/EE) mutant does not
support this hypothesis as the sole mechanism. Alterna-
tively, parthenolide could stabilize the kinase activation
loop in the inactive conformation despite the presence of
the neighboring negatively charged phosphorylated serines
(or glutamates, in the case of the constitutively active SS/
EE mutant). Structural studies of a parthenolide:IKKL
co-crystal will address this possibility. Parthenolide bind-
ing could also induce dissociation of the IKK complex,
leading to a decrease in IKK activity. However, our pre-
liminary data indicate that there is no dissociation of
IKKK, IKKL or NEMO from the core complex upon
parthenolide binding (data not shown). Nevertheless, giv-
en the recent discovery of the additional complex compo-
nent, CIKS/Act1 [35,36], this model remains a possibility.
Given the structural and biological similarities between
parthenolide and other compounds found in anti-in£am-
matory herbal medicines, our ¢ndings shed light on the
biological mechanism of this interesting class of natural
products. Many biologically active sesquiterpene lactones
possess an K-methylene Q-lactone moiety. We show that
upon reduction of this functional group, parthenolide
loses its ability to inhibit TNFK induction of NF-UB tran-
scriptional activity. Furthermore, reduced parthenolide
has no e¡ect on the TNFK-induced DNA binding activity
of NF-UB or on the PMA-induced ear edema in an in vivo
model of in£ammation. Reduced parthenolide’s lack of
biological activity also correlates with its inability to
bind IKKL. Thus, these ¢ndings demonstrate the impor-
tance of the K-methylene Q-lactone moiety and provide a
molecular basis for the biological activity of other anti-
in£ammatory sesquiterpene lactones possessing an K-
methylene Q-lactone moiety.
Given its importance as a critical player in the in£am-
matory signaling pathway, IKKL is an attractive target for
anti-in£ammatory therapeutic development. Our ¢nding
that parthenolide directly targets IKKL may serve as the
basis for the generation of new anti-in£ammatory agents.
4. Signi¢cance
Feverfew and several other anti-in£ammatory medicinal
herbs are rich in sesquiterpene lactones, a group of com-
pounds thought to mediate the anti-in£ammatory nature
of these plants. Recently, parthenolide, a sesquiterpene
lactone found in Feverfew, was suggested to target a com-
ponent of the IKK complex. However, no direct target
was identi¢ed. Earlier reports by LyM et al. [17] and Ru«ng-
eler et al. [18] suggested that helenalin, another sesquiter-
pene lactone, directly alkylates p65, one subunit of the
dimeric transcription factor NF-UB, yet no direct bio-
chemical evidence was provided to prove this hypothesis.
In this report, we show the direct interaction between par-
thenolide and IKKL, one of the catalytic subunits of the
IKK complex. Using a biotinylated derivative of parthe-
nolide as an a⁄nity reagent, we demonstrate covalent
modi¢cation of IKKL by biotinylated parthenolide.
Mass spectrometric analysis revealed that cysteine 179
was modi¢ed by parthenolide. Moreover, by site-directed
mutagenesis, we showed that an IKKL mutant (C179A)
abolished parthenolide’s inhibitory e¡ect on IKKL. Since
parthenolide could form a covalent adduct via nucleo-
philic attack on the epoxide or the exocyclic methylene,
we further investigated the molecular interaction between
parthenolide and its binding target by reducing the exocy-
clic methylene. Reduced parthenolide lacks both in vivo
and in vitro anti-in£ammatory properties. The results pre-
sented here provide a possible explanation for partheno-
lide’s anti-in£ammatory properties and may aid in the
development of a new class of anti-in£ammatory agents.
5. Materials and methods
5.1. Cell culture
All cell culture reagents were purchased from Gibco BRL (Gai-
thersburg, MD, USA). HeLa cells were cultured in Dulbecco’s
modi¢ed essential medium (DMEM) supplemented with 10% fe-
tal bovine serum and PSF (an antibiotic-antimycotic (penicillin,
streptomycin and Fungizone0 from Gibco-BRL). Transfections
were done using Fugene6 transfection reagent (Roche, Indianap-
olis, IN, USA) following the manufacturer’s instructions. Cells
were harvested 24 h after transfection. Parthenolide (Sigma)
and biotinylated parthenolide were dissolved in dimethyl sulfox-
ide (DMSO) and used at the concentrations indicated. Cells were
treated with parthenolide, biotinylated parthenolide or vehicle
(DMSO) 1 h (or otherwise indicated) prior to harvesting.
TNFK (Roche) was added at a ¢nal concentration of 20 ng/ml.
Cells were harvested in NP-40 lysis bu¡er (50 mM Tris^HCl,
150 mM NaCl, 1% NP-40, 10% v/v glycerol) supplemented with
pepstatin (10 Wg/ml), leupeptin (10 Wg/ml), aprotinin (5 Wg/ml)
and 1 mM phenylmethylsulfonyl £uoride at 4‡C.
5.2. Syntheses of biotinylated parthenolide and reduced
parthenolide
Biotinylated parthenolide was prepared ¢rst by oxidation of
parthenolide (Aldrich) with selenium dioxide and tert-butylhydro-
peroxide to furnish the allylic alcohol, as previously described
[37]. The allylic alcohol was then esteri¢ed with 12-(Fmoc amino)
dodecanoic acid under Mitsunobu conditions. Removal of the
Fmoc group with tetrabutylammonium £uoride followed by cou-
pling with biotin using N-[dimethylamino)-1H -1,2,3-triazolo-
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[4,5-b]pyridino-1-ylmethylene]-N-methylmethanaminimum hexa-
£uorophosphate N-oxide/di-isopropylethylamine yielded biotinyl-
ated parthenolide. The biotinylated product was veri¢ed by 1H
nuclear magnetic resonance (NMR) and electrospray mass spec-
troscopy. 1H NMR (CDCl3, 500 MHz) N 6.26 (d, 1H, J = 4.0 Hz),
5.87 (brs, 2H), 5.69 (t, 1H, J = 7.5, 9.0 Hz), 5.55 (d, 1H, J = 3.5
Hz), 5.19 (brs, 1H), 4.66 (d, 1H, J = 12.5 Hz), 4.54 (brs, 1H), 4.47
(d, 1H, J = 12.5 Hz), 4.32 (brs, 1H), 3.87 (t, 1H, J = 9.25 Hz),
3.24^3.14 (m, 3H), 2.95^2.91 (m, 2H), 2.87 (d, 1H, J = 9.5 Hz),
2.75 (m, 1H), 2.33^2.19 (m, 6H), 1.70^1.12 (m). ES-MS m/z
(M+H) calcd. for C37H58N3O7S 688.40, found 688.57.
Hydrogenation of parthenolide was carried out in ethyl acetate
under 1 atm using a 5% molar ratio of palladium (10% wt on
activated carbon) at room temperature to yield reduced parthe-
nolide. The reduced product was veri¢ed by 1H NMR spectros-
copy.
1H NMR (CDCl3, 500 MHz) N 5.20 (dd, 1H, J = 2.25, 11.9
Hz), 3.85 (t, 1H, J = 9.07 Hz), 2.70 (d, 1H, J = 8.96 Hz), 2.45^
1.10 (m).
5.3. EMSA
Total HeLa cell lysate was prepared in NP-40 lysis bu¡er.
Aliquots (10 Wg protein) were mixed in binding bu¡er (10 mM
Tris^HCl, pH 7.5, 1 mM MgCl2, 0.5 mM ethylenediaminetetra-
acetic acid, 0.5 mM dithiothreitol (DTT), 4% glycerol, 0.05 mg/ml
poly(dI-dC), 50 mM NaCl) at room temperature for 10 min fol-
lowed by incubation with 32P-radiolabeled NF-UB consensus oli-
gos, 5P-AGTTGAGGGGACTTTCCCAGGC-3P (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for an additional 20
min. DNA binding activity was analyzed by 4% non-denatured
PAGE and autoradiography. The speci¢city of NF-UB binding
was veri¢ed by supershift with (2 Wg) p65 antibodies (Santa Cruz
Biotechnology) (data not shown).
5.4. Immunoprecipitation, kinase assays and immunoblotting
Cell lysates prepared in NP-40 lysis bu¡er with phosphatase
inhibitors (10 mM NaF, 0.5 mM sodium vanadate and 20 mM
L-glycerophosphate) were incubated with antibodies (2^5 Wg) for
1 h. Protein A- or G-conjugated agarose beads were then added
and incubated overnight. Immunoprecipitated complex was then
washed three times with lysis bu¡er and twice with 25 mM Tris^
HCl pH 7.5. Kinase assays were performed by incubating the
immunoprecipitate in kinase reaction bu¡er (25 mM Tris^HCl
pH 7.5, 10 mM MgCl2, 2 mM DTT, 50 WM ATP and phospha-
tase inhibitors) with 5 WCi [Q-32P]ATP and 2 Wg bacterially ex-
pressed GST-IUBK (1^54) in a reaction volume of 50 Wl for 20
min at 30‡C. The phosphorylated substrate was then a⁄nity-
puri¢ed with glutathione-Sepharose resin (Pharmacia) and ana-
lyzed by SDS^PAGE, autoradiography, and Western blotting.
Anti-IKKL and anti-Flag (M2) antibodies were purchased from
Santa Cruz Biotechnology and Sigma, respectively.
5.5. Luciferase assay
HeLa cells were transfected with 100 ng each of pFLuc2xUB
[38] and pRL-TK vector (Promega) DNA for 24 h. After incu-
bation with parthenolide, reduced parthenolide, or vehicle
(DMSO) for 1 h, transfected cells were stimulated for 5 h with
TNFK (10 ng/ml). Luciferase assays were performed according to
the manufacturer’s instructions.
5.6. Mouse ear edema assay
Parthenolide (0.5 mg/ear), reduced parthenolide (0.5 mg/ear) or
vehicle (DMSO:methanol 1:3) was applied to the right ears of
three groups of ¢ve mice for 15 min before PMA treatment (5 Wg
in 20 Wl ethanol/ear). Left ears of mice were treated with vehicle
alone as a control. Six hours after PMA application, ear thick-
ness was measured using a micrometer as described [38].
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